Study For The Dynamic Variation Of Serum Glypican-3 In Patients With Primary Hepatic Cancer Between Pre-and Post-TACE

Objective To investigate the dynamic variation of serum glypican-3(GPC3) in patients with primary hepatic cancer(PHC) received transcatheter arterial chemoembolization(TACE) therapy and explore the application value of GPC3 expression in the diagnosis and treatment efficiently.Methods The serum GPC3 levels of 47 PHC patients were tested by enzyme linked immunosorbent assay(ELISA) before treatment(comprising 37 given TACE therapy and 10 received the radical excision),at the time point of 7 days and 1 month after TACE.The GPC3 expression of 18 hepatocirrhosis patients and 33 healthy persons was test with the same method.Results The level of serum GPC3 in 47 PHC patients,33 healthy persons and 18 hepatocirrhosis patients were 3.74±2.71ng/mL,0.67±0.30 ng/mL and 0.74±0.39 ng/mL respectively.Serum GPC3 levels in PHC patients were significantly higher than those with hepatocirrhosis or healthy people(P＜0.05).The GPC3 expression was significantly different in tumors size,(P＜0.05).However,the expression of GPC3 was not obviously difference with tumor thrombi in portal vein(PVTT),tumor number,age,sex or pathogen.2ng/ml as the cutoff value of,GPC3 detection in diagnosis and specificity was 65.96%and 94.44%respectively.Within the 47 cases, the positive rate of AFP detection is 70%and the positive rate combined AFP detection was 87.23%.Within the 37 cases of PHC patients received TACE.the level of GPC3 were 2.56±1.81ng/mL,2.37±2.01ng/mL at the time point of 7 days,1 month after TACE,both of which are lower than pre-treatment(4.01±3.55ng/mL) (P＜0.05).The GPC3 level of the low-tendency to metastatic recurrence group were 4.87±3.71 ng/mL,1.65±0.96 ng/mL and 1.23±1.18 ng/mL respectively.In the higer group,GPC3 level at the 7 days after TACE(1.81±1.51 ng/mL) is lower than before pre-TACE(5.00±5.21 ng/mL),but it pick up again before second-time TACE (5.87±5.32 ng/mL).There is a linear correlation between the fall of GPC3 and AFP pre-and post-TACE(p＜0.05). Conclusion GPC3 in the serum of PHC patients express higher,compared to the cirrhosis and the healthy persons.Our result data implicated that the serum GPC3 can be used as a marker for the diagnosis of PHC.The combined detection of GPC3 and AFP may enhance the diagnostic sensitivity.Analysis of GPC3 may be used as the tool for the evaluation of TACE treatment efficiency and the judgment for second-time TACE.Furthermore,it may be used for the prediction of tumor recrudescence.